Drug Profile


Alternative Names: 742457; GSK 742457; RVT-101; SB-742457

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Axovant Sciences; GlaxoSmithKline
  • Class Antidementias; Nootropics
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Dementia; Lewy body disease

Most Recent Events

  • 09 Jan 2017 Axovant Sciences completes enrolment in the Phase-III MINDSET trial in Alzheimer's disease (Adjunctive treatment) in USA, Taiwan, Hungary, Slovakia, Singapore, Serbia, Poland, South Korea, Italy, France, Czech Republic, Croatia, Canada, Australia, Australia, Argentina (PO)
  • 09 Dec 2016 Efficacy data from the phase III MINSET trial in Alzheimer's disease released by Axovant Sciences
  • 07 Oct 2016 Axovant Sciences plans the phase II/III HEADWAY-DLB Extension trial for Lewy body disease in USA (PO, Tablet) (NCT02928445)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top